|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||56.55 - 57.25|
|52-week range||51.78 - 86.31|
|Beta (5Y monthly)||0.59|
|PE ratio (TTM)||14.01|
|Forward dividend & yield||0.30 (0.53%)|
|Ex-dividend date||09 May 2022|
|1y target est||N/A|
(Reuters) -Swiss drug contract manufacturer Lonza said core earnings gained 20.7% in 2021, shored up by demand for the substances it supplies for new mRNA COVID-19 vaccines. Full-year core earnings before interest, tax, depreciation and amortisation (EBITDA) rose to 1.67 billion Swiss francs ($1.82 billion), up from 1.38 billion a year earlier, it said in a statement on Wednesday. For this year, Lonza predicted "low to mid-teens" sales growth, when excluding currency swings, as well as core EBITDA margin improvement from 30.8% in 2021.
In this Motley Fool Live video recorded on Nov. 3, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether investors should have Lonza on their watchlists. Keith Speights: Brian, one final topic before we get to questions.
By Dhirendra Tripathi